Antibody-drug conjugate shows promising early results in Phase I trial in sarcoma patients
An antibody-drug conjugate, a type of drug that targets and enters cancer cells like a Trojan Horse, has shown promising early results across diverse types of soft tissue sarcoma in a Phase I trial. The findings were presented at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.